Trending Stock News

Ellington Financial (EFC) Analysts See $0.28 EPS; Shorts at Abbott Laboratories (ABT) Raised By 36.59%

Abbott Laboratories (NYSE:ABT) Logo

Abbott Laboratories (NYSE:ABT) had an increase of 36.59% in short interest. ABT’s SI was 13.23M shares in April as released by FINRA. Its up 36.59% from 9.69 million shares previously. With 8.36M avg volume, 2 days are for Abbott Laboratories (NYSE:ABT)’s short sellers to cover ABT’s short positions. The SI to Abbott Laboratories’s float is 0.77%. The stock increased 0.39% or $0.23 during the last trading session, reaching $59.06. About 869,261 shares traded. Abbott Laboratories (NYSE:ABT) has risen 34.85% since April 13, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Analysts expect Ellington Financial LLC (NYSE:EFC) to report $0.28 EPS on May, 3.They anticipate $0.08 EPS change or 22.22% from last quarter’s $0.36 EPS. EFC’s profit would be $8.58M giving it 13.21 P/E if the $0.28 EPS is correct. After having $0.22 EPS previously, Ellington Financial LLC’s analysts see 27.27% EPS growth. The stock decreased 0.27% or $0.04 during the last trading session, reaching $14.79. About 12,756 shares traded. Ellington Financial LLC (NYSE:EFC) has declined 5.64% since April 13, 2017 and is downtrending. It has underperformed by 17.19% the S&P500.

Investors sentiment increased to 1.44 in 2017 Q4. Its up 0.80, from 0.64 in 2017Q3. It improved, as 5 investors sold Ellington Financial LLC shares while 11 reduced holdings. 9 funds opened positions while 14 raised stakes. 13.48 million shares or 2.67% less from 13.85 million shares in 2017Q3 were reported. Arrowstreet Cap Limited Partnership holds 0.01% in Ellington Financial LLC (NYSE:EFC) or 267,328 shares. Financial Grp reported 1.62% in Ellington Financial LLC (NYSE:EFC). Ameriprise stated it has 0% of its portfolio in Ellington Financial LLC (NYSE:EFC). 218,624 were reported by Deutsche Financial Bank Ag. Hightower Advisors Ltd invested in 59,611 shares or 0.01% of the stock. Royal National Bank & Trust Of Canada, a Ontario – Canada-based fund reported 11,000 shares. Endowment Ltd Partnership has 0.04% invested in Ellington Financial LLC (NYSE:EFC). Renaissance Technology Ltd Liability Com invested in 0% or 218,564 shares. Susquehanna Group Inc Llp invested in 21,467 shares or 0% of the stock. Edge Wealth Management Limited Liability Company invested 0.08% of its portfolio in Ellington Financial LLC (NYSE:EFC). Virtu Fincl Limited Co reported 14,568 shares. Manufacturers Life Ins Commerce The stated it has 0% in Ellington Financial LLC (NYSE:EFC). Two Sigma Limited Liability Corp holds 14,244 shares. Bb&T Llc stated it has 56,842 shares. The Illinois-based Gp One Trading Ltd Partnership has invested 0% in Ellington Financial LLC (NYSE:EFC).

Ellington Financial LLC, through its subsidiary Ellington Financial Operating Partnership LLC, operates as a specialty finance firm in the United States. The company has market cap of $453.27 million. It primarily acquires and manages mortgage-related assets, including residential mortgage-backed securities backed by prime jumbo, Alt-A, manufactured housing, and subprime residential mortgage loans; RMBS for which the principal and interest payments are guaranteed by the U.S. government agency or the U.S. government-sponsored entity; residential mortgage loans; commercial mortgage-backed securities; commercial mortgage loans and other commercial real estate debt; mortgage servicing rights; and real property and mortgage-related derivatives. It has a 14.22 P/E ratio. The firm also invests in corporate debt and equity securities, including distressed debt, collateralized loan obligations, and non-mortgage-related derivatives; and other financial assets, including private debt and equity investments in mortgage-related entities.

Among 7 analysts covering Ellington Financial (NYSE:EFC), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Ellington Financial had 24 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Ellington Financial LLC (NYSE:EFC) earned “Hold” rating by Keefe Bruyette & Woods on Tuesday, September 12. The stock has “Buy” rating by Maxim Group on Tuesday, October 11. FBR Capital initiated the stock with “Outperform” rating in Thursday, April 21 report. The company was downgraded on Wednesday, November 8 by FBR Capital. Maxim Group maintained the shares of EFC in report on Thursday, August 13 with “Buy” rating. Deutsche Bank maintained Ellington Financial LLC (NYSE:EFC) rating on Monday, August 10. Deutsche Bank has “Buy” rating and $22.75 target. Maxim Group maintained it with “Buy” rating and $1900 target in Monday, April 9 report. The rating was maintained by Maxim Group with “Buy” on Thursday, February 18. Maxim Group maintained it with “Buy” rating and $19.0 target in Tuesday, November 7 report. Maxim Group maintained Ellington Financial LLC (NYSE:EFC) rating on Friday, August 4. Maxim Group has “Buy” rating and $2000 target.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $103.14 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 219.55 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

Since October 23, 2017, it had 1 insider buy, and 19 insider sales for $28.95 million activity. Another trade for 1,645 shares valued at $96,728 was sold by BIRD ROGER. Blaser Brian J sold $1.73M worth of Abbott Laboratories (NYSE:ABT) on Wednesday, January 31. On Tuesday, January 30 the insider Fussell Stephen R sold $14.27M. Another trade for 96,603 shares valued at $5.43M was made by Salvadori Daniel Gesua Sive on Monday, October 23. The insider Bracken Sharon J sold 2,100 shares worth $126,559. 6,284 Abbott Laboratories (NYSE:ABT) shares with value of $375,381 were sold by Contreras Jaime. PEDERSON MICHAEL J had sold 459 shares worth $27,213.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of ABT in report on Wednesday, January 24 with “Buy” rating. BTIG Research downgraded Abbott Laboratories (NYSE:ABT) on Monday, January 22 to “Neutral” rating. The rating was maintained by BMO Capital Markets on Monday, July 10 with “Hold”. Argus Research maintained Abbott Laboratories (NYSE:ABT) rating on Friday, July 21. Argus Research has “Buy” rating and $62 target. The company was maintained on Thursday, July 20 by Stifel Nicolaus. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, October 9 report. On Friday, October 6 the stock rating was maintained by JP Morgan with “Neutral”. The company was maintained on Thursday, October 19 by Citigroup. Jefferies maintained the shares of ABT in report on Thursday, August 4 with “Buy” rating. The firm earned “Overweight” rating on Thursday, January 25 by JP Morgan.

Investors sentiment increased to 0.91 in 2017 Q4. Its up 0.04, from 0.87 in 2017Q3. It is positive, as 52 investors sold Abbott Laboratories shares while 558 reduced holdings. 123 funds opened positions while 430 raised stakes. 1.22 billion shares or 0.64% more from 1.21 billion shares in 2017Q3 were reported. Raymond James Fincl Svcs Advsrs holds 0.15% in Abbott Laboratories (NYSE:ABT) or 420,274 shares. Susquehanna Intll Grp Limited Liability Partnership holds 0% of its portfolio in Abbott Laboratories (NYSE:ABT) for 86,986 shares. Oxbow Ltd Liability has invested 0.08% of its portfolio in Abbott Laboratories (NYSE:ABT). First Wilshire Securities Mngmt invested 0.08% of its portfolio in Abbott Laboratories (NYSE:ABT). Blair William Il holds 772,184 shares. Everence Incorporated accumulated 0.61% or 48,721 shares. 20,468 were reported by Bankshares Of Stockton. Cooke & Bieler Ltd Partnership has invested 1.82% in Abbott Laboratories (NYSE:ABT). Signaturefd Ltd Limited Liability Company holds 0.11% of its portfolio in Abbott Laboratories (NYSE:ABT) for 16,213 shares. Dumont Blake Investment Advsr Limited Company has invested 0.42% in Abbott Laboratories (NYSE:ABT). Interocean Cap Ltd Company holds 0.06% or 7,593 shares in its portfolio. Murphy Cap holds 0.18% or 22,657 shares. Schnieders Capital Ltd Liability Co reported 71,214 shares stake. Alphamark Advisors Ltd Liability holds 100 shares. Fincl Bank Hapoalim Bm holds 0.13% or 10,640 shares.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *